JP2010501576A5 - - Google Patents

Download PDF

Info

Publication number
JP2010501576A5
JP2010501576A5 JP2009525648A JP2009525648A JP2010501576A5 JP 2010501576 A5 JP2010501576 A5 JP 2010501576A5 JP 2009525648 A JP2009525648 A JP 2009525648A JP 2009525648 A JP2009525648 A JP 2009525648A JP 2010501576 A5 JP2010501576 A5 JP 2010501576A5
Authority
JP
Japan
Prior art keywords
day
effective amount
therapeutically effective
use according
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009525648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501576A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/018770 external-priority patent/WO2008024485A2/en
Publication of JP2010501576A publication Critical patent/JP2010501576A/ja
Publication of JP2010501576A5 publication Critical patent/JP2010501576A5/ja
Pending legal-status Critical Current

Links

JP2009525648A 2006-08-25 2007-08-23 ビタミンｄ化合物及び追加の治療薬の投与を含む癌の治療方法 Pending JP2010501576A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93492406P 2006-08-25 2006-08-25
PCT/US2007/018770 WO2008024485A2 (en) 2006-08-25 2007-08-23 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent

Publications (2)

Publication Number Publication Date
JP2010501576A JP2010501576A (ja) 2010-01-21
JP2010501576A5 true JP2010501576A5 (enExample) 2010-10-07

Family

ID=39107444

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525648A Pending JP2010501576A (ja) 2006-08-25 2007-08-23 ビタミンｄ化合物及び追加の治療薬の投与を含む癌の治療方法

Country Status (9)

Country Link
EP (2) EP2425874A3 (enExample)
JP (1) JP2010501576A (enExample)
KR (1) KR20090060306A (enExample)
CN (1) CN101528309A (enExample)
AU (1) AU2007287099A1 (enExample)
CA (2) CA2661546A1 (enExample)
IL (1) IL197212A0 (enExample)
NO (1) NO20091191L (enExample)
WO (1) WO2008024485A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196308A1 (en) * 2009-01-27 2010-08-05 Jimenez Joaquin J Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
SG176105A1 (en) 2009-06-26 2011-12-29 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
US20120135002A1 (en) * 2009-07-16 2012-05-31 Ivan Cruz Moura Compounds and Methods for the Treatment of Cancer
CN103108871B (zh) 2010-09-16 2014-09-10 诺华股份有限公司 17α-羟化酶/C17,20-裂合酶抑制剂
US20120116381A1 (en) 2010-11-05 2012-05-10 Houser Kevin L Surgical instrument with charging station and wireless communication
US9029399B2 (en) 2011-04-28 2015-05-12 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
US9801844B2 (en) * 2012-05-24 2017-10-31 The Research Foundation Of The City University Of New York Methods and compositions for the treatment of cancer
IL312316A (en) 2012-09-26 2024-06-01 Aragon Pharmaceuticals Inc Antiandrogens for the treatment of castration-resistant prostate cancer without metastases
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
EP2988752A4 (en) 2013-04-24 2017-01-18 Salk Institute for Biological Studies Vitamin d receptor/smad genomic circuit gates fibrotic response
JP2016530219A (ja) 2013-06-05 2016-09-29 ソーク インスティテュート フォー バイオロジカル スタディーズ Ｃｘｃｌ１２活性に関与する疾患を処置するためのビタミンｄ受容体アゴニスト
WO2019023149A1 (en) 2017-07-24 2019-01-31 Salk Institute For Biological Studies USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES
JOP20200076A1 (ar) 2017-10-16 2020-04-30 Aragon Pharmaceuticals Inc مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120722A (en) 1984-02-08 1992-06-09 Hoffmann-La Roche Inc. Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia
US4857518A (en) 1984-10-04 1989-08-15 Wisconsin Alumni Research Foundation Hydroxylated 24-homo-vitamin D derivatives and methods for preparing same
US4717721A (en) 1985-05-30 1988-01-05 Howard W. Bremer Sidechain homo-vitamin D compounds with preferential anti-cancer activity
US4866048A (en) 1985-08-02 1989-09-12 Leo Pharmaceutical Products Ltd. Novel vitamin D analogues
US5145846A (en) 1988-01-20 1992-09-08 Hoffmann-La Roche Inc. Vitamin D3 analogs
US4851401A (en) 1988-07-14 1989-07-25 Wisconsin Alumni Research Foundation Novel cyclopentano-vitamin D analogs
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
GB8915770D0 (en) 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
DE4101953A1 (de) 1991-01-19 1992-07-23 Schering Ag 23-oxa-derivate in der vitamin-d-reihe, verfahren zu ihrer herstellung diese derivate enthaltende pharmazeutische praeparate sowie deren verwendung als arzneimittel
DE4141746A1 (de) 1991-12-13 1993-06-17 Schering Ag 20-methyl-substituierte vitamin d-derivate
DK0633893T3 (da) * 1992-03-31 2000-04-17 Btg Int Ltd 17-Substituerede steroider, der er nyttige ved cancerbehandling
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5547947A (en) 1993-03-11 1996-08-20 Hoffmann-La Roche Inc. Methods of treatment
GB9622590D0 (en) 1996-10-30 1997-01-08 Leo Pharm Prod Ltd Chemical compounds
WO1999049870A1 (en) 1998-03-27 1999-10-07 Oregon Health Sciences University Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders
ES2300323T3 (es) * 2000-03-02 2008-06-16 Univ Pittsburgh Quimioterapia combinada.
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents

Similar Documents

Publication Publication Date Title
JP2010501576A5 (enExample)
JP2010501575A5 (enExample)
JP6445123B2 (ja) 癌を治療するための方法及び組成物
JP2012082215A5 (enExample)
US9370526B2 (en) Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer
ES2356408T3 (es) Medicamento que incluye al menos un gestágeno.
IL320452A (en) Combination therapy for prostate cancer
HRP20110129T1 (hr) Sastavi koji sadrže kristalni trans-(+/-)-delta-9-tetrahidrokanabinol
JP2020516646A5 (enExample)
JP2017516802A5 (enExample)
EP1429778A1 (en) Protopanaxadiol and protopanaxatriol and their use as synergistic anti-cancer agents
JP2009511590A5 (enExample)
TWI441639B (zh) 用於治療卵巢癌之包含紫杉醇之組合
US6759397B2 (en) Ginsenoside chemotherapy
JP2010538066A5 (enExample)
JP2010504307A5 (enExample)
US20100303937A1 (en) Novel composition to increase testosterone levels
JP2019513706A5 (enExample)
CN118045089A (zh) 呋喹替尼的药物制剂及其应用
EP1699464A1 (en) Menstrual cycle control and improvement of conception rates in females
JP2019535830A5 (enExample)
CN115300624A (zh) 人参皂苷联合pd-1阻断剂在制备抗头颈鳞癌药物中的应用
CN101623287B (zh) 一种屈螺酮类似物的治疗更年期综合症的药物组合物
US11986507B1 (en) Micronutrient composition to improve men's health
CN113164503B (zh) 3β-O-Glc-DM和20S-O-Glc-DM治疗肺癌或结直肠癌的用途